Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma

Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer. It frequently emerges in the presence of immunosuppression states such as myeloproliferative syndrome (MS). MS is treated with ruxolitinib, a selective JAK1 and JAK2 inhibitor. Avelumab, an anti PDL-1 inhibitor, is the sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonerba, Luciana, Di Trolio, Rossella, Grimaldi, Antonio, Tucci, Aniello, Leo, Emilio, Ingenito, Concetta, Costabile, Ferdinando, Ragone, Gianluca, Savastano, Beatrice, Uzzauto, Maria Teresa, Belsito Petrizzi, Valeria, Di Lorenzo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642625/
https://www.ncbi.nlm.nih.gov/pubmed/33194706
http://dx.doi.org/10.3389/fonc.2020.579914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642625/
https://www.ncbi.nlm.nih.gov/pubmed/33194706
http://dx.doi.org/10.3389/fonc.2020.579914

Ejemplares similares